Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
InMed Pharmaceuticals Inc. is a global biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of rare cannabinoids and cannabinoid-based therapeutics. The company combines its validated drug development expertise with its IntegraSyn™ cannabinoid manufacturing approach to develop novel therapies for diseases with high unmet medical needs. InMed also operates InMed Biosciences, a B2B division focused on supplying high-quality, regulatory-compliant rare cannabinoids to the health and wellness sector, and includes its subsidiary BayMedica, which specializes in synthetic and biosynthetic cannabinoid production.
The Vancouver headquarters serves as the primary center for corporate administration, strategic planning, financial operations, clinical development oversight, regulatory affairs, and business development activities.
Located in a prominent business area, offering access to Vancouver's robust life sciences community, financial institutions, and transportation links.
InMed fosters a dynamic, science-driven, and collaborative work environment. The culture emphasizes innovation, scientific rigor, and a commitment to developing solutions for unmet medical needs.
The headquarters is crucial for InMed's strategic decision-making, management of its global R&D programs, and engagement with the North American and international investment communities (listed on NASDAQ and TSX).
InMed Pharmaceuticals operates with a global perspective, headquartered in Canada and with R&D and subsidiary operations in the United States (California and Nevada). The company collaborates with Contract Manufacturing Organizations (CMOs) in the US and Europe for GMP-compliant production of cannabinoids. Its pharmaceutical development programs target global regulatory approvals, and its InMed Biosciences division markets rare cannabinoids to the international health and wellness industry.
Suite 350 – 409 Granville Street
Vancouver
British Columbia
Canada
Address: c/o University of British Columbia, 2329 West Mall, Vancouver, BC V6T 1Z4, Canada (Leased Lab Space)
Facilitates access to advanced research infrastructure, academic collaborations, and a skilled talent pool within one of Canada's leading research universities, supporting InMed's early-stage R&D pipeline.
Address: Leased lab facility in Novato, CA (e.g., historically 100 Wood Hollow Dr, Novato, CA 94945 - specific current leased address may vary)
Strengthens InMed's cannabinoid manufacturing capabilities and R&D in the U.S., leveraging California's prominent biotech ecosystem and serving as a key site for producing rare cannabinoids.
Address: 9605 S. Eastern Avenue, Suite 240, Las Vegas, Nevada 89123, USA
Provides an administrative base for BayMedica's operations within the United States.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, InMed Pharmaceuticals' leadership includes:
InMed Pharmaceuticals has been backed by several prominent investors over the years, including:
In the past 12 months, InMed Pharmaceuticals appointed Jonathan Tegge as its new Chief Financial Officer in August 2023. No other major executive departures or hires at the senior executive level have been publicly announced during this period.
Discover the tools InMed Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
While InMed Pharmaceuticals does not officially publish its email format, a common pattern used by companies in the biopharmaceutical industry, and potentially by InMed, is [first_initial][last_name]@[company_domain].com. For example, 'jdoe@inmedpharma.com'.
[first_initial][last]@inmedpharma.com
Format
eadams@inmedpharma.com
Example
70%
Success rate
GlobeNewswire via InMed Pharmaceuticals Website • May 15, 2024
InMed Pharmaceuticals announced its financial results for the third quarter of fiscal year 2024, ended March 31, 2024. The company provided updates on its pharmaceutical drug development programs, including INM-901 for Alzheimer's disease and INM-089 for epidermolysis bullosa, and highlighted progress in its cannabinoid manufacturing activities and commercial B2B sales....more
GlobeNewswire via InMed Pharmaceuticals Website • January 23, 2024
InMed Pharmaceuticals announced the commercial launch of Delta 9-dominant Tetrahydrocannabivarin (Δ9-THCV) through its B2B subsidiary, InMed Biosciences. This launch expands its portfolio of rare cannabinoids available for use in the health and wellness sector, manufactured to high quality and regulatory standards....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including InMed Pharmaceuticals, are just a search away.